Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma

(2018) Milind Javle et al.   JOURNAL OF CLINICAL ONCOLOGY

Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study

(2017) Lucia Nogova et al.   JOURNAL OF CLINICAL ONCOLOGY

Cholangiocarcinoma — evolving concepts and therapeutic strategies

(2017) Sumera Rizvi et al.   Nature Reviews Clinical Oncology

Therapeutic options for intrahepatic cholangiocarcinoma

(2017) Manojkumar Bupathi et al.   HEPATOBILIARY SURGERY AND NUTRITION

Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice

(2016) Apurva Jain et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Polyclonal SecondaryFGFR2Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma

(2016) Lipika Goyal et al.   Cancer Discovery

Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation

(2016) Terence G. Hall et al.   PLoS One

Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma

(2015) A. Moeini et al.   CLINICAL CANCER RESEARCH

Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma

(2015) Mitesh J. Borad et al.   CURRENT OPINION IN GASTROENTEROLOGY

Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations

(2015) Leandro H. Gallo et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors

(2015) Josep Tabernero et al.   JOURNAL OF CLINICAL ONCOLOGY

Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23

(2015) Chiara Degirolamo et al.   NATURE REVIEWS DRUG DISCOVERY

Massive parallel sequencing uncovers actionable FGFR2–PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma

(2015) Daniela Sia et al.   Nature Communications

Fibroblast Growth Factor Receptor 2 (FGFR2) Is Required for Corneal Epithelial Cell Proliferation and Differentiation during Embryonic Development

(2015) Jinglin Zhang et al.   PLoS One

Second-line chemotherapy in advanced biliary cancer: a systematic review

(2014) A. Lamarca et al.   ANNALS OF ONCOLOGY

Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer

(2014) B. Escudier et al.   CLINICAL CANCER RESEARCH

Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma

(2014) Alexandra R. Grassian et al.   CURRENT OPINION IN GASTROENTEROLOGY

Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma

(2014) Rondell P. Graham et al.   HUMAN PATHOLOGY

Cholangiocarcinoma

(2014) Nataliya Razumilava et al.   LANCET

Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications

(2014) Chaitanya R. Churi et al.   PLoS One

Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma

(2014) Mitesh J. Borad et al.   PLoS Genetics

Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma

(2013) Yasuhito Arai et al.   HEPATOLOGY

Intrahepatic Cholangiocarcinoma: Management Options and Emerging Therapies

(2013) Rebecca M. Dodson et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS

Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma

(2012) Benjamin R. Kipp et al.   HUMAN PATHOLOGY

Molecular Regulation of Phosphate Metabolism by Fibroblast Growth Factor-23–Klotho System

(2011) Chung-Yi Cheng et al.   ADVANCES IN CHRONIC KIDNEY DISEASE

Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study

(2011) Jeeyun Lee et al.   LANCET ONCOLOGY

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

(2010) Juan Valle et al.   NEW ENGLAND JOURNAL OF MEDICINE

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Systemic Therapy for Biliary Tract Cancers

(2008) A. F. Hezel et al.   ONCOLOGIST